

Celebrating
50
years
1968-2018



Icahn School
of Medicine at
**Mount
Sinai**

15th Annual Mount Sinai Inflammatory Bowel Disease Consultant's Course

*Reaching Remission in IBD:
New targets – New strategies*

Friday, October 12, 2018

Goldwurm Auditorium

Icahn School of Medicine at Mount Sinai

1425 Madison Avenue at 98th Street

New York, NY

Course Directors:

Jean-Frédéric Colombel, MD

Professor of Medicine
Director of the Susan and Leonard
Feinstein IBD Clinical Center and
The Leona M. and Harry B. Helmsley
Charitable Trust Inflammatory Bowel
Disease Center

Marla Dubinsky, MD

Professor of Pediatrics and Medicine
Chief Pediatric Gastroenterology
and Hepatology
Co-Director Susan and Leonard Feinstein
IBD Clinical Center

Asher Kornbluth, MD

Clinical Professor of Medicine
Icahn School of Medicine at Mount Sinai

James F. Marion, MD

Professor of Medicine
Director of Education and Outreach
Susan and Leonard Feinstein IBD Clinical Center

Sponsored by:
The Dr. Henry D. Janowitz Division of Gastroenterology
Department of Medicine
Icahn School of Medicine at Mount Sinai

<https://mssm.cloud-cme.com>



15th Annual Mount Sinai Inflammatory Bowel Disease Consultant's Course

October 12, 2018

7:30-8:05 Registration

8:05-8:15 Introduction and Welcome

Session 1A The Problem of Remission

8:15-8:35 New Targets/New Drugs: Strategies to Remission **Bruce E. Sands, MD**

8:35-8:55 When May I Stop/Reduce my Medication? **Jean-Frédéric Colombel, MD**

8:55-9:15 TDM and Staging Response **Ryan Ungaro, MD**

Session 1B The Problem of Remission in the Refractory Patient

9:15-9:35 Treating the Inpatient with Severe UC **Asher Kornbluth, MD**

9:35-9:55 Stem Cell Management of Fistulae **Amy L. Lightner, MD**

9:55-10:15 Bone Marrow Transplant and IBD: Ready for Prime Time? **Louis J. Cohen, MD**

10:15-10:30 [Panel Discussion/Q&A](#)

10:30-10:45 Break

Session 2 Pathophysiology of IBD: New Suspects, New Mechanisms

10:45-11:05 **Lloyd Mayer Memorial Lecture**
Using Epidemiology to Pursue Etiology in IBD **Charles Bernstein, MD**

11:05-11:25 Environmental Pollutants and Toxins and IBD **Manish K. Arora, PhD, MPH**

11:25-11:45 The Role of Integrin Blocking Therapies in Understanding IBD **Saurabh Mehandru, MD**

11:45-12:05 Update on FMT and IBD **Ari Grinspan, MD**

12:05-12:25 IPAA's: What Do They Tell Us About IBD? **Maia Kayal, MD**

12:25-12:45 [Panel Discussion/Q&A](#)

Session 3 Working Lunch Lecture:

12:45-1:15 Diet, Marijuana and Supplements in IBD Science, Hope or Hoax? **Adam F. Steinlauf, MD**

Session 4 Challenging Clinical Problems in IBD

1:25-1:45 Rashes and Hair Loss in IBD: EIM or AE **Jacob Levitt, MD**

1:45-2:05 Surveillance and IBD: Thinking Outside of the Lumen **James F. Marion, MD**

2:05-2:25 IBD and IBS **Robert Hirten, MD**

2:25-2:45 IBD in the Elderly **Benjamin L. Cohen, MD**

2:45-3:05 New Drugs and The Pregnant and Nursing Mother **Marla Dubinsky, MD**

3:05-3:20 [Panel Discussion/Q&A](#)

3:20-3:30 Conclusion

Program Goals

The Mount Sinai Inflammatory Bowel Diseases Consultant's Course will provide an in-depth review of strategies for participants to better diagnosis, classify and achieve remission in patients with Crohn's disease and ulcerative colitis. State-of-the-art lectures will be given by expert faculty on optimizing therapies, innovative treatment of fistula, epidemiology of IBD and challenging clinical scenarios such as cancer prevention in colitis, IBD in pregnant and nursing mothers and the elderly. The goal is to meet the need of our IBD patients by addressing sub-optimal disease control, preventable disease complications, and potential negative consequences of therapy such as serious infections and cancer.

The Icahn School of Medicine at Mount Sinai course directors have selected experts in this field to lend their expertise to highlight the latest advances in the treatment to a disease that affects about 1.6 million people in the US. There will be many opportunities for audience interaction and participation at this year's Course.

Program Objectives

At the conclusion of the conference, participants will be able to:

- Identify new targets, new drugs, new strategies in IBD treatment.
- Describe treatment options for special populations with inflammatory bowel disease: pregnant and nursing mothers, hospitalized patients, and the elderly.
- Analyze the epidemiology of IBD with special consideration of the role of environmental pollutants and toxins.
- Analyze controversial topics in the multidisciplinary management of IBD such as the role of diet, marijuana and supplements.

Who Should Attend

Gastroenterologists, Colorectal Surgeons, Primary Care Physicians, PAs and other healthcare professionals caring for patients with IBD or colorectal cancer.

Accreditation Statement

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 7.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Location

Goldwurm Auditorium
Icahn Medical Institute
1425 Madison Avenue at 98th St.
New York, NY 10029

Parking & Directions

Parking is available on East 99th Street between Madison and Park Avenues.
Directions: www.icaahn.mssm.edu/about/visiting

Registration Fees

- Physicians \$325
- Mount Sinai Health System (MSHS) Physicians \$300
- Allied Health Professionals \$100
- MSHS Allied Health Professionals \$75
- Fellows and Residents \$75
- Industry \$125

Online Registration

<https://mssm.cloud-cme.com>

Hotel Accommodations

Please contact Denise Newman at (718)835-4911 or email dnew229@aol.com.

Special Needs

Icahn School of Medicine is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you would like to attend and require any special accommodations, please contact The Page and William Black Post-Graduate School at (212)731-7950.

For additional conference information, please call the **Office of CME: (212)731-7950** or email: cme@mssm.edu.

15th Annual Mount Sinai Inflammatory Bowel Disease Consultant's Course

*Reaching Remission in IBD:
New targets – New strategies*

Friday, October 12, 2018

Goldwurm Auditorium
Icahn School of Medicine at Mount Sinai
1425 Madison Avenue at 98th Street
New York, NY

Register Online

 <https://mssm.cloud-cme.com>

Registration Fees

- Physicians \$325
- Mount Sinai Health System (MSHS) Physicians \$300
- Allied Health Professionals \$100
- MSHS Allied Health Professionals \$75
- Fellows and Residents \$75
- Industry \$125

Or Register by Check



Mail this form with your check to:

Icahn School of Medicine at Mount Sinai
The Page and William Black Post-Graduate School
One Gustave L. Levy Place, Box 1193
New York, NY 10029-6574

LAST NAME FIRST NAME (MD, RN, etc.)

ADDRESS

CITY STATE ZIP

() TELEPHONE INSTITUTION/AFFILIATION

EMAIL SPECIALTY

Enclosed is my check for \$_____ payable to:

The Page and William Black Post-Graduate School

For security purposes, credit card payment cannot be accepted by mail or fax. Please visit www.icaahn.mssm.edu/cme/courses to register and pay by credit card: Visa, MC, AMEX.

Cancellation policy

All refund and cancellation requests must be emailed to the CME office at cme@mssm.edu by October 1, 2018. Cancellations after this date are not eligible for a refund. An administrative fee of \$50 will be deducted from your refund. No refunds will be issued for registration fees that are equal or less than \$50.



Celebrating
50
years
1968-2018



Icahn School
of Medicine at
**Mount
Sinai**

Icahn School of Medicine at Mount Sinai

The Page & William Black Post-Graduate School
One Gustave L. Levy Place, Box 1193
New York, NY 10029

**15th Annual
Mount Sinai
Inflammatory
Bowel Disease
Consultant's Course**

*Reaching Remission in IBD :
New targets – New strategies*

October 12, 2018

<https://mssm.cloud-cme.com>

**Icahn School of Medicine
at Mount Sinai
Planning Committee /
Course Directors**

Jean-Frédéric Colombel, MD

Professor of Medicine
Director of the Susan and Leonard
Feinstein IBD Clinical Center and
The Leona M. and Harry B. Helmsley
Charitable Trust Inflammatory Bowel
Disease Center

Marla Dubinsky, MD

Professor of Pediatrics and Medicine
Chief Pediatric Gastroenterology and
Hepatology Co-Director Susan and
Leonard Feinstein IBD Clinical Center

Asher Kornbluth, MD

Clinical Professor of Medicine
Icahn School of Medicine at Mount Sinai

James F. Marion, MD

Professor of Medicine
Director of Education and Outreach
Susan and Leonard Feinstein IBD
Clinical Center

Guest Faculty

Charles Bernstein, MD

Distinguished Professor of Medicine
University of Manitoba
Winnipeg, Manitoba

Amy L. Lighter, MD

Assistant Professor of Surgery
Mayo Clinic College of Medicine
Rochester, MN

**Icahn School of Medicine
at Mount Sinai Faculty**

Manish K. Arora, PhD, MPH

Professor of Environmental Medicine &
Public Health

Benjamin L. Cohen, MD

Assistant Professor of Medicine

Louis J. Cohen, MD

Assistant Professor of Medicine

Ari Grinspan, MD

Assistant Professor of Medicine

Robert Hirten, MD

Assistant Professor of Medicine

Maia Kayal, MD

Fellow Gastroenterology Department

Jacob Levitt, MD

Professor of Dermatology

Saurabh Mehandru, MD

Associate Professor of Medicine

Bruce E. Sands, MD

Dr. Burrill B. Crohn Professor of Medicine
Chief of The Dr. Henry D. Janowitz
Division of Gastroenterology

Adam F. Steinlauf, MD

Associate Professor of Medicine

Ryan Ungaro, MD

Assistant Professor of Medicine

FACULTY DISCLOSURE: It is the policy of Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course materials.